ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
Two Onc Docs
00:00
Episode focus and BRUIN context
Kareen summarizes the episode focus and mentions BRUIN-314 and FDA approval context for pirtobrutinib.
Play episode from 00:13
Transcript
